We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
WorldQuant Millennium Advisors
76
WorldQuant Millennium Advisors
New York
$11M +$6.06M +218,496 +110%
CI
77
Cooper Investors
Australia
$10.8M – – –
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$10.8M -$11.1M -401,921 -50%
Squarepoint
79
Squarepoint
New York
$10.6M -$6.17M -222,513 -36%
BNP Paribas Asset Management
80
BNP Paribas Asset Management
France
$10.5M +$6.04M +217,767 +120%
National Pension Service
81
National Pension Service
South Korea
$9.71M – – –
SCI
82
S&CO Inc
Massachusetts
$9.45M +$477K +17,210 +5%
Pictet Asset Management
83
Pictet Asset Management
Switzerland
$9.22M -$7.07M -254,997 -42%
Robeco Institutional Asset Management
84
Robeco Institutional Asset Management
Netherlands
$8.95M +$7.34M +264,900 +356%
DFCM
85
Dark Forest Capital Management
Puerto Rico
$8.93M +$9.08M +327,659 +2,974%
New York State Common Retirement Fund
86
New York State Common Retirement Fund
New York
$8.64M +$450K +16,251 +5%
Goldman Sachs
87
Goldman Sachs
New York
$8.42M -$7.87M -283,806 -47%
Tudor Investment Corp
88
Tudor Investment Corp
Connecticut
$8.24M +$8.22M +296,452 +1,847%
Allspring Global Investments
89
Allspring Global Investments
North Carolina
$8.2M +$8.54M +308,102 +11,204%
State Board of Administration of Florida Retirement System
90
State Board of Administration of Florida Retirement System
Florida
$8.15M +$185K +6,660 +2%
ECM
91
Evergreen Capital Management
Washington
$7.87M +$1.37M +49,284 +20%
Jane Street
92
Jane Street
New York
$7.47M +$5.36M +193,416 +215%
Manulife (Manufacturers Life Insurance)
93
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7.38M -$81.4M -2,934,926 -91%
T. Rowe Price Associates
94
T. Rowe Price Associates
Maryland
$7.13M +$242K +8,722 +3%
Barclays
95
Barclays
United Kingdom
$7M -$536K -19,341 -7%
MIF
96
Mediolanum International Funds
Ireland
$6.89M +$723K +26,072 +10%
GT
97
Glenmede Trust
Pennsylvania
$6.54M -$4.33M -156,381 -39%
APM
98
Advanced Portfolio Management
New York
$6.33M +$3.33M +120,000 +100%
DB
99
Danske Bank
Denmark
$6.31M +$180K +6,500 +3%
BA
100
Bridgewater Associates
Connecticut
$6.3M -$3.67M -132,471 -36%
2 3
4
5 6

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.